Stable Liquid-Crystal Emulsion for Medical Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing thermotropic liquid crystal emulsions in aqueous polyvinyl alcohol solutions are not stable, release unpleasant odors, and are unsuitable for industrial applications due to high energy requirements and lack of optical continuity, making them inadequate for medical uses such as early breast cancer diagnosis.
Innovation Solution
A stable thermooptically responsive emulsion is achieved by using a water-acetone-alcohol solution of polyvinyl alcohol with boric acid and nonoxynol-5, with specific molecular weight and hydrolysis ranges, and a controlled preparation method involving temperature and mixing conditions to create a stable and repeatable emulsion with optimal drop size and viscosity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If conventional aqueous polyvinyl alcohol solutions containing formaldehyde are used as continuous phase, then emulsion can be formed, but the emulsion releases unpleasant odors and has low stability
Solution Approach 1:
The patent changes the chemical composition parameters of the continuous phase by replacing formaldehyde-containing polyvinyl alcohol solutions with a new system containing boric acid (0.1-1.0%) and nonoxynol-5 (1-2%) surfactant. This parameter change eliminates the unpleasant formaldehyde odor while maintaining emulsion stability through the synergistic action of boric acid crosslinking and surfactant stabilization.
Solution Approach 2:
The patent introduces boric acid as an intermediary substance that acts as a crosslinking agent between polyvinyl alcohol chains, forming a stable gel network in the continuous phase. This intermediary mechanism provides structural stability to the emulsion without requiring formaldehyde, thereby eliminating odor issues while maintaining reliability.
2Manufacturing precision
If high rotation speed homogenizers (above 12000 l/min) are used for emulsification, then emulsion can be formed, but energy consumption increases and cooling system is required
Solution Approach 1:
The patent changes the emulsification process parameters by reducing the rotation speed from above 12000 l/min to 3000-8000 l/min. This parameter reduction decreases energy consumption and eliminates the need for cooling systems, while the new continuous phase composition (boric acid + nonoxynol-5) compensates for the reduced mechanical energy input by providing chemical stabilization.
Solution Approach 2:
The patent partially replaces the mechanical emulsification system with a chemical stabilization system. Instead of relying solely on high-speed mechanical homogenization, the invention uses boric acid crosslinking and surfactant action to stabilize the emulsion, thereby reducing dependence on high-energy mechanical input while maintaining uniformity.
3Reliability
If microencapsulation process is used for liquid crystal encapsulation, then liquid crystals are protected, but optical continuity is lost which is critical for medical applications
Solution Approach 1:
The patent applies segmentation by creating discrete liquid crystal droplets (1-10 μm diameter) dispersed in the continuous phase, rather than using microencapsulation with thick wall structures. This segmentation approach protects the liquid crystals through physical dispersion while maintaining optical continuity because the droplet size and spacing allow light to pass through the emulsion uniformly, which is essential for thermographic imaging in medical applications.
Solution Approach 2:
The patent replaces the thick encapsulation walls of microencapsulation with a thin-film-like continuous phase matrix formed by polyvinyl alcohol, boric acid, and surfactant. This continuous phase acts as a flexible medium that surrounds and protects liquid crystal droplets while maintaining optical transparency and continuity, enabling medical imaging applications.
4Ease of manufacture
If polyvinyl alcohol with inappropriate molecular weight or hydrolysis degree is used, then emulsion preparation is simplified, but viscosity and drop size control becomes unreliable
Solution Approach 1:
The patent establishes precise parameter ranges for polyvinyl alcohol (molecular weight 50,000-150,000; hydrolysis degree 83-98%) and adds boric acid (0.1-1.0%) and nonoxynol-5 (1-2%) to the continuous phase. These parameter changes create optimal conditions for emulsion formation that are both easy to manufacture (within standard industrial ranges) and highly repeatable (producing consistent viscosity and drop size), resolving the contradiction between ease and precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces a stable, odor-free liquid-crystal emulsion with controlled viscosity and drop size, suitable for industrial and medical applications, particularly in early breast cancer diagnosis, ensuring optical continuity and ease of preparation.
Implementation Method 1
the main function of polyvinyl alcohol in the emulsion, in combination with small amount, preferably from 1 to 2% by weight, of surfactant (nonoxynol-5) as a dispersing agent, is to act as a thickening agent
Implementation Method 2
The function of polyvinyl alcohol in the phase after emulsion application, is in turn to act as a film-forming agent and partially encapsulating agent
Implementation Method 3
nonoxynol-5 (ethoxylated nonylphenol, a product of addition about 5 molecules ethylene oxide to nonylphenol) as a dispersing agent
Implementation Method 4
from 0.1 to 1.0% boric acid
Data Source
AI summary
The present invention relates to liquid-crystal emulsion for the use in a thermo-optical matrix to an early diagnosis of mammary gland neoplasmic lesions. It contains a mixture of thermotropic liquid crystals and polyvinyl alcohol. The liquid-crystal emulsion contains 14 to 48% by weight (on a dry matter basis) of the thermotropic compounds mixture and 50 to 86% by weight (on a dry matter basis) of polyvinyl alcohol. The present invention also relates to a method for preparing liquid-crystal emulsion.